scholarly journals Update on the mechanisms of action of anti‑TNF-α antibodies and their clinical implications in inflammatory bowel disease

2016 ◽  
Vol 126 (10) ◽  
pp. 772-780 ◽  
Author(s):  
Piotr Eder ◽  
Krzysztof Linke ◽  
Janusz Witowski
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Mechanisms Of Action ◽  
Clinical Implications ◽  
Tnf Α ◽  
Inflammatory Bowel

scholarly journals Cutaneous Manifestations in Biological-Treated Inflammatory Bowel Disease Patients: A Narrative Review

2021 ◽  
Vol 10 (5) ◽  
pp. 1040
Author(s):  
Jo L. W. Lambert ◽  
Sofie De Schepper ◽  
Reinhart Speeckaert
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Cutaneous Manifestations ◽  
Cutaneous Infections ◽  
Tnf Α ◽  
Common Skin ◽  
Receptor Blockers ◽  
Infusion Reactions ◽  
Inflammatory Bowel ◽  
Lichenoid Reactions

The biologic era has greatly improved the treatment of Crohn’s disease and ulcerative colitis. Biologics can however induce a wide variety of skin eruptions, especially those targeting the TNF-α and Th17 pathway. These include infusion reactions, eczema, psoriasis, lupus, alopecia areata, vitiligo, lichenoid reactions, granulomatous disorders, vasculitis, skin cancer, and cutaneous infections. It is important to recognize these conditions as treatment-induced adverse reactions and adapt the treatment strategy accordingly. Some conditions can be treated topically while others require cessation or switch of the biological therapy. TNF-α antagonists have the highest rate adverse skin eruptions followed by ustekinumab and anti-integrin receptor blockers. In this review, we provide an overview of the most common skin eruptions which can be encountered in clinical practice when treating IBD (Inflammatory bowel disease) patients and propose a therapeutic approach for each condition.

scholarly journals Inflammatory bowel disease: the role of inflammatory cytokine gene polymorphisms

2004 ◽  
Vol 13 (3) ◽  
pp. 181-187 ◽  
Author(s):  
Joanna Balding ◽  
Wendy J. Livingstone ◽  
Judith Conroy ◽  
Lesley Mynett-Johnson ◽  
Donald G. Weir ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Disease Incidence ◽  
Strong Association ◽  
Tnf Α ◽  
Genes Encoding ◽  
Inflammatory Processes ◽  
Inflammatory Bowel ◽  
Cytokine Gene Polymorphisms

THE mechanisms responsible for development of inflammatory bowel disease (IBD) have not been fully elucidated, although the main cause of disease pathology is attributed to up-regulated inflammatory processes. The aim of this study was to investigate frequencies of polymorphisms in genes encoding pro-inflammatory and anti-inflammatory markers in IBD patients and controls. We determined genotypes of patients with IBD (n=172) and healthy controls (n=389) for polymorphisms in genes encoding various cytokines (interleukin (IL)-1β, IL-6, tumour necrosis factor (TNF), IL-10, IL-1 receptor antagonist). Association of these genotypes to disease incidence and pathophysiology was investigated. No strong association was found with occurrence of IBD. Variation was observed between the ulcerative colitis study group and the control population for the TNF-α-308 polymorphism (p=0.0135). There was also variation in the frequency of IL-6-174 and TNF-α-308 genotypes in the ulcerative colitis group compared with the Crohn's disease group (p=0.01). We concluded that polymorphisms in inflammatory genes are associated with variations in IBD phenotype and disease susceptibility. Whether the polymorphisms are directly involved in regulating cytokine production, and consequently pathophysiology of IBD, or serve merely as markers in linkage disequilibrium with susceptibility genes remains unclear.

Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease

2012 ◽  
Vol 18 (12) ◽  
pp. 2209-2217 ◽  
Author(s):  
Casper Steenholdt ◽  
Magid Al-khalaf ◽  
Jrn Brynskov ◽  
Klaus Bendtzen ◽  
Ole. Thomsen ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Clinical Implications ◽  
Inflammatory Bowel ◽  
Antibody Levels

scholarly journals Synthesis and evaluation of 6-heteroarylamino-2,4,5-trimethylpyridin-3-ols as inhibitors of TNF-α-induced cell adhesion and inflammatory bowel disease

MedChemComm ◽  
2018 ◽  
Vol 9 (8) ◽  
pp. 1305-1310 ◽  
Author(s):  
Sang Won Park ◽  
Suhrid Banskota ◽  
Pallavi Gurung ◽  
You Jin Jin ◽  
Han-eol Kang ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Cell Adhesion ◽  
Bowel Disease ◽  
Tnf Α ◽  
Inflammatory Bowel ◽  
Anti Inflammatory

Novel series of anti-inflammatory bowel disease (IBD) agent was identified through TNF-α-induced cell adhesion.

Sign in / Sign up

Export Citation Format

Share Document